AKT1 and cancer: Our findings reveal molecular insight into how the IR‐HER2/AKT/NF‐κB‐RNF126‐MRE11‐ATR/CHK1 pathway is activated and how DDR choices are determined in cells during DSBs, in turn providing innovative paradigms for the DNA damage response and therapeutic applications for cancer treatment.